Latest Asx News

InvestSMART Group Limited swung to a net loss of $575,633 in FY26, marking a sharp reversal from the prior year’s profit, amid a strategic pivot including a pending $16 million sale of its Intelligent Investor business.

SCX.ai Holdings Limited is set to raise $40 million through a fully underwritten IPO at $0.30 per share, aiming to scale its sovereign AI inferencing platform built on ASIC hardware within Australian data centres. The company targets the fast-growing AI IaaS market with a focus on secure, low-latency AI workloads.

Australis Oil & Gas Ltd posted a $2.6 million net loss for 1H 2026 amid sharply reduced production volumes but is progressing its Tuscaloosa Marine Shale development with a key partner and a planned Q4 well spud.

Synertec Corporation has been awarded the delivery phase of the Brooklyn Pump Station IO Upgrade by Melbourne Water, extending a contract valued at approximately $1.1 million. The project modernises critical water infrastructure with advanced operational technology.

MA Credit Income Trust (ASX: MA1) launches a voluntary off-market buy-back for up to 2.5% of units at net asset value, aiming to provide liquidity and capital management benefits to unitholders.

Ironbark Balanced Income Limited reported a 5.6% decline in net profit to $2.89 million for FY2026, while its investment portfolio delivered a solid 7.8% return, outperforming its benchmark and maintaining fully franked dividends.

Energy Fuels’ acquisition of Australian Strategic Materials (ASM) has officially closed following Federal Court approval, triggering suspension of ASM trading and setting the stage for shareholder payments and new listings.

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

Recce Pharmaceuticals has secured ethics approval to add an active-controlled arm to its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, enabling head-to-head comparison against existing antibiotics.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

Canadian Phosphate Limited’s initial 2026 drilling at Wapiti has successfully intersected phosphate mineralisation in all eight holes, extending the known Main Zone strike by over 3km. Assay results are pending, with a resource update planned for late 2026.